Prodia Targets 20,000 More Participants in 2026 After 40,000 Joined Last Year’s Free Dementia Screening

Jakarta, 9 February 2026 – PT Prodia Widyahusada Tbk (ticker symbol: PRDA) is set to organize another Free Dementia Screening Program in 2026, following the high number of participants and their great reception to the program in 2024–2025, which successfully had a total of 40,000 participants across Indonesia. This program is intended for seniors and aims to reach 20,000 participants across Indonesia. The sustainability of this initiative affirms Prodia’s commitment to promoting early detection of cognitive disorders while implementing the Environmental, Social, and Governance (ESG) sustainability pillars, particularly the social aspect by Promoting Healthcare Services for All, which aligns with Sustainable Development Goal 3: Good Health and Well-Being.

Dementia is characterized by cognitive impairment, including loss of memory, language, and thinking abilities, which can affect a person’s independence and quality of life. Therefore, early detection is crucial to determine appropriate preventive measures and treatment from the outset. According to Alzheimer’s Disease International, around 55 million people worldwide are living with dementia, and this figure is expected to triple by 2050. In Indonesia alone, it is estimated that more than 1.2 million people have dementia, necessitating increased awareness of and access to early detection of dementia.

Prodia’s Business & Marketing Director, Indriyanti Rafi Sukmawati, said, “The success of the Dementia Screening Program is inseparable from the great enthusiasm and reception from the public since we first implemented this program. This indicates a growing awareness among the people, particularly seniors, of the risks of dementia and the importance of early detection as a preventive measure to maintain quality of life in old age,” Indriyanti said.

In 2026, Prodia will once again organize a Free Dementia Screening Program for people aged 50 years and older at Prodia Clinic branches. The screening is held in stages, starting with the AD-8 INA Questionnaire, followed by the MOCA-INA administered by a Prodia doctor for participants with a score ≥2. Participants who are indicated to experience a decline in cognitive functioning will be referred for further tests and consultations with a neurologist or geriatric internist at the Prodia Senior Health Center located in Jakarta, Surabaya, and Makassar. In 2025, this program drew nearly 30,000 participants, exceeding the target of 20,000 by more than 140%. This figure represents a significant increase from the previous year’s participants, which was around 10,000. This increase was thanks to various public education activities that raised awareness of the importance of early detection of dementia.

On the same occasion, Prodia’s AVP of Business, Indri Marya Wulandari, added that participants in this program receive not only screening services but also advanced education and referrals for further consultations and tests as needed. “We hope this initiative will encourage people to care more about their brain health and take preventive measures to mitigate the risk of dementia,” she said.

Prodia continues to strengthen various sustainability programs aimed at improving health literacy and equal access to health services for society. To do so, Prodia develops health services that adopt personalized medicine, including the Prodia Senior Health Center, which prioritizes a holistic care approach tailored to everyone’s needs. By sustaining and expanding this initiative, Prodia hopes to encourage the public to be more proactive in maintaining their cognitive function, making the most of early detection, and taking preventive measures to mitigate the risk of dementia and improve quality of life.

#Prodia #DementiaScreening #BrainHealth #EarlyDetection

******
 

About PT Prodia Widyahusada Tbk.

Prodia Clinical Laboratory was initially established in Solo on 7 May 1973 by a group of idealist pharmacists. From the very first, Dr. Andi Widjaja, MBA, along with the other founders have been committed to present the best check-up result through dedicated services. 

All Prodia branches have been accredited by both national and international bodies. One of them is from the College of American Pathologists (CAP), a professional organization in the field of health laboratories in the United States that has received international recognition for 10 consecutive years. Under CAP Accreditation, Prodia’s clinical laboratory standards are evaluated against international benchmarks, making its test results acceptable for use domestically and overseas. It implies that the quality of the test results from Prodia’s laboratory is equal to those of international laboratories. 

On 7 December 2016, the Indonesia Stock Exchange officially listed the initial public offering of Prodia as the 15th issuer in 2016, with the ticker symbol “PRDA.” In that corporate action, Prodia offered 187.5 million shares. Accordingly, the fund raised from the company’s initial public offering (IPO) was Rp1.22 trillion.

As of 31 December 2025, Prodia has a service network comprising 402 outlets across 81 cities, 113 districts, and 34 provinces in Indonesia. Some of them are Prodia Health Care (PHC)—a personalized medicine-based wellness clinic—and specialty clinics, including Prodia Children’s Health Center (PCHC), Prodia Women’s Health Centre (PWHC), and Prodia Senior Health Center (PSHC).     

Prodia has also launched Prodia Contact, which includes a call center at 1500-830 and an online virtual personal assistant, Ask Prodia (TANIA), accessible via WhatsApp at 08551500830, Telegram at @prodia.id, Facebook Messenger at @prodia.id, and Prodia’s Web Widget at www.prodia.co.id. Prodia’s services can also be accessed through the U by Prodia app, available on the App Store & PlayStore. 

For more information, visit www.prodia.co.id or contact: